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Review Article
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Abstract: Delirium is a frequent condition in patients in a palliative care situation and most often 
associated with substantial burden or even danger for the persons concerned as well as caregivers and health-
care-professionals. Despite the lack of randomized-controlled-trials (RCTs) benzodiazepines and neuroleptic 
agents are used extensively in palliative care for the pharmacological management of delirium. A focused 
review for RCTs assessing pharmacotherapy with benzodiazepines and neuroleptics for the treatment 
of delirium in patients treated in a palliative care or hospice setting published in 2017 was performed in 
PubMed. A narrative summary of the findings of the RCTs and practical recommendation are presented. 
Of 42 publications, two RCTs could be included. One trial assessed the use of lorazepam (in addition to 
haloperidol) in case of agitation, the other placebo or risperidone or haloperidol in delirious palliative care 
patients. Neither risperidone nor haloperidol were superior compared to placebo, but were associated with 
higher mortality and morbidity. Lorazepam (along with haloperidol) reduced agitation in patients with 
delirium compared to placebo (along with haloperidol), but was unable to reduce the severity and incidence 
of delirium. It is of importance to note that psychopharmacotherapy with antipsychotics is mainly indicated 
for the hyperactive form of delirium and psychotic symptoms (e.g., delusions or hallucinations) in the hyper- 
and hypoactive delirium. Severe agitation and aggressivity can be an indication for neuroleptics, when non-
pharmacological interventions fail, whereas the use of benzodiazepines has to be limited to critical situations 
where neuroleptics cannot be applied and cases of delirium due to alcohol withdrawal. Both substances can 
aggravate, precipitate or mask delirium, result adverse events with substantial distress or unfavorable survival 
outcomes for the patients. Thus, they should only be used in severely symptomatic patients and the duration 
of the medication has to be limited in time. When delirium symptoms decay the psychopharmacotherapy has 
to be tapered. More important than psychopharmacotherapy, the thorough investigation and treatment of 
potentially reversible causes of delirium (e.g., pharmacotherapy, infection) and the routine identification of 
patients at risk for delirium along with prophylactic measures are essential. The recently published landmarks 
RCTs provide moderate evidence to adopt recommendations from other medical specialties (i.e., intensive 
care, geriatrics) to the field of palliative care.
Keywords: Delirium; palliative care palliative medicine; antipsychotic agents; benzodiazepines; evidence based 
medicine
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Introduction
The recently revised definition of delirium according to 
the fifth edition of the Diagnostic and Statistical Manual 
(DSM) of the American Psychiatric Association (1) 
acknowledges that the diagnosis of delirium is an 
umbrella construct. While in DSM versions prior to 
DSM-5 alterations of consciousness (content or level of 
consciousness) and level of arousal were core features, both 
terms were omitted in DSM-5 (2). The DSM-5 definition 
now relies on disturbance of cognition such as memory 
deficit, disorientation, language, visuospatial ability, or 
perception (1). In addition, disturbance in attention (i.e., 
reduced ability to direct, focus, sustain, and shift attention) 
and awareness (reduced orientation to the environment) 
are mandatory features (3-5). However, while the DSM-
5 definition is used widely in clinical and research settings, 
it does not represent a consensus definition in all fields 
of medicine. For example, in contrast to dementia (6-12), 
delirium develops over a short period (hours and days), 
fluctuates in severity during the course of day and is 
often associated with an impaired day/night pattern. In 
contrast to the International Classifications of Diseases 
10 (13) altered psychomotor activity is not part of the 
DSM 5 definition, but delirium can present as hyper- or 
hypoactive delirium (14). Both states, but especially the 
hypoactive form are often unrecognized by physician and 
this deficit has not improved over time resulting in at least 
$164 billion in annual health care expenditures alone in 
the US (15). Delirium is a frequent and life-threatening 
condition, associated with unfavorable short- and long-
term prognosis (16,17), and diverse and multifactorial 
etiologies (18). In palliative care, it is especially prevalent 
in patients near the end of life and most often results in 
profound distress for patients and caregivers (17,19). A 
major pharmacologic strategy in this situation is palliative 
sedation (20). In hospitals, nursing homes and home care, 
delirium is a serious problem, leading to substantial health 
care costs and associated high levels of mortality (21-23). 
Delirium is a complex and challenging situation for health 
care professionals because it is often irreversible and in 
case of agitated and aggressive patients sometimes even a 
risk for those involved in caring for the patient (formal and 
informal caregivers) (24,25). To overcome these situations, 
benzodiazepines and neuroleptics are widely used to treat 
delirium in various clinical settings, including palliative care 
(25,26). Outside the field of palliative care, neuroleptics and 
benzodiazepines have been examined in trials for example 
in a postoperative, intensive-care or geriatric setting 
(15,27-29). Here, benzodiazepines were found to provoke, 
aggravate or mask delirium (15,27-29), reduce survival and 
sometimes even lead to long-term cognitive impairment 
(15,27-30). Thus, many clinicians avoid them (29,30) and 
guidelines and meta-analyses do not recommend their use 
(26,29,31,32), with delirium due to withdrawal being an 
important exception (29,30). Neuroleptics are extensively 
used to treat delirium or “distressing behavioral and 
psychological symptoms” (33) in various settings (34), as 
for example in the elderly, even though no substance has 
yet been approved for this indication and neuroleptics have 
shown to increase mortality (34-36). Therefore, guidelines 
recommend neuroleptics to be reserved for severe psychotic 
symptoms and for the hyperactive form of delirium with 
careful consideration of patient safety (36). Nevertheless, 
many clinicians continue to administer conventional (e.g., 
haloperidol) or atypical neuroleptics (e.g., risperidone) 
willingly to treat delirium in palliative care (37,38) or even 
as prophylaxis for delirium (39). 
The aim of this publication is to obtain and discuss 
novel evidence from randomized, placebo-controlled trials 
(RCTs) published in 2017 on the use of benzodiazepines 
or neuroleptics in the treatment of delirium in palliative 
care and to provide basic recommendations for the 
pharmacotherapy in this setting.
Methods
A focused review for RCTs assessing psychopharmacotherapy 
with benzodiazepines or neuroleptics of delirium in patients 
treated in a palliative care or hospice setting was performed. 
No language restrictions were being applied and no specific 
definition for “palliative care” or “hospice” was demanded. 
Instead, the studies were deemed eligible if the authors of 
the publications reported of patients under palliative-, end-
of-life-, comfort-, supportive- or hospice care, regardless 
of the definition of “palliative care” or “hospice” they 
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relied on. To obtain and discuss only novel and widely 
accessible key-publications, only RCTs published in 2017 
in PubMed listed medical journals were being included. A 
narrative summary and no meta-analysis of the findings of 
the RCTs were intended. No a-priori registration of the 
review protocol (e.g., in PROSPERO) or risk of bias (RoB) 
analysis was done due to the narrow and focused scope of 
this review. 
The search included the following queries connected via 
the Boolean operator “AND”:
Query 1-Condition: delirium [tw1];
Query 2-Setting: palliative care [tw] OR hospice [tw] OR 
palliative medicine [tw] OR end-of-life [tw];
Query 3-Studydesign: randomi*2 [tw] OR trial [MeSH] 
OR randomized controlled trial [MeSH]. 
1, the builder tw (“text word”) searches title, abstract, 
MeSH headings and subheadings (single words and phrases) 
and other terms field such as author-supplied keywords; 2, 
the asterisk (“*”) is the PubMed truncation symbol.
Two researchers (Jan Gaertner and Walter Prikoszovich) 
independently screened the search findings and excluded 
hits according to title and abstract. Potential disagreement 
was resolved by the consultation of another author (Steffen 
Eychmueller). 
Results
On December 17th 2017, the search yielded 42 publications. 
After exclusion of 40 hits, two remained for analysis (Table S1).
Study 1: Agar et al. (40) 
Methods: the study was performed to compare the 
efficacy of risperidone or haloperidol versus placebo 
in relieving distress among patients with delirium who 
were receiving palliative care at 11 Australian inpatient 
hospice- or hospital palliative care facilities. A double 
blind, parallel-arm, dose-titrated randomized clinical 
trial was conducted. Patients with a Nursing Delirium 
Screening Scale (NuDESC) sum score of at least 1 
were included. Patients received titrated doses of oral 
risperidone, haloperidol, or placebo solution for 72 hours. 
There was also an option to continue the blinded study 
medication for an additional 48 h if a partial response 
occurred or to allow a dose taper with symptom resolution. 
The researchers doses were age-adjusted, with patients 
65 years or younger receiving a 0.5 mg loading dose (either 
risperidone or haloperidol) administered with the first dose 
of 0.5 mg, then 0.5 mg maintenance doses every 12 hours. 
Doses could be titrated by 0.25 mg on day 1 and by 0.5 mg 
thereafter to a maximum dose of 4 mg/d. Patients older than 
65 years received 50% of the loading, initial, and maximum 
doses. Doses were increased if the sum of NuDESC 
scores for items 2, 3 and 4 (behavioral, communication 
and perceptual items) was 1 or more at the most recent 
assessment, conducted every 8 hours. Dose reduction to 
the prior dose was performed in the case of adverse effects, 
resolution of delirium [Memorial Delirium Assessment 
Scale (MDAS) score <7 for 48 hours], or resolution of 
symptoms (all NuDESC item scores <1 for 48 hours). All 
patients received treatment of potentially reversible causes 
of delirium, if these were identifiable and treatment seemed 
indicated. In addition, non-pharmacologic measure such 
as adequate hydration, vision and hearing aids, presence 
of family, and reorientation were provided as appropriate 
and available. Subcutaneous midazolam (2.5 mg, every 
2 hours) was administered if patients scored 2 on the 
NuDESC item for “inappropriate behavior” or “illusions 
and hallucinations”. For serious extrapyramidal adverse 
effects, benztropine (1 to 2 mg) was available intravenously. 
The primary outcome of the study was the average of the 
last 2 delirium symptom scores on day 3, compared to the 
baseline score. 
Results: the intention-to-treat (ITT) analysis included 
247 patients. Of these, 218 (88%) were cancer patients and 
85% were women. Mean age was 74.9 [standard deviation 
(SD): 9.8]. Study participants had mild to moderate delirium 
(median baseline MDAS scores ranged from 13.7 to 15.1), 
and were predominantly male (65.6%) with a mean age of 
74.9 years. The majority had a cancer diagnosis (88.3%) and 
baseline Australia-modified Karnofsky Performance Status 
(AKPS) scores ranged from 30% to 50%. The risperidone 
group included 82 patients, 81 received haloperidol, and 
84 placebos. At the end of the study, delirium symptom 
scores of patients in the risperidone arm were significantly 
higher compared to the placebo group [average: 0.48 units; 
95% confidence interval (CI), 0.09−0.86; P=0.02] in the 
primary ITT analysis. The findings for patients receiving 
haloperidol were also significantly worse compared to 
placebo: Here, delirium symptom scores were 0.24 Units 
higher (95% CI, 0.06−0.42; P=0.009) compared to the 
control group. Concerning adverse events, patients in both 
intervention groups experienced more extrapyramidal 
effects (risperidone: 0.73; 95% CI, 0.09−1.37; P=0.03; 
haloperidol: 0.79; 95% CI, 0.17−1.41; P=0.01). Overall 
survival was significantly higher for patients receiving 
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placebo compared to those receiving haloperidol [hazard 
ratio (HR), 1.73; 95% CI, 1.20−2.50; P=0.003]. Compared 
to patients’ risperidone, placebo patients’ overall survival 
did not differ significantly (HR, 1.29; 95% CI, 0.91−1.84; 
P=0.14).
Authors’ conclusions: treatment of underlying causes of 
delirium and non-pharmacologic management of delirium is 
more effective in treating distressing symptoms of delirium 
than risperidone and haloperidol.
Study 2: Hui et al. (41) 
Methods: the study was conducted to compare the effect 
of lorazepam versus placebo on agitation in patients with 
delirium who were also receiving neuroleptics (haloperidol). 
The double-blind, parallel-group RCT recruited patients 
with advanced cancer that were treated on an acute 
palliative care ward of an US comprehensive cancer center 
who had at least 2 days of delirium with documented 
episodes of agitation before enrollment. All patients started 
on a standardized open-label regimen with haloperidol (2 
mg) every 4 hours intravenously and another 2 mg every 
hour as needed for agitation. The Richmond Agitation and 
Sedation Scale [RASS; range, −5 (“unarousable”) to 4 (“very 
agitated or combative”)] score was obtained two hourlies 
until it was at least 1 or more (RASS score 1: “Restless-
Anxious or apprehensive but movements not aggressive or 
vigorous”). The study protocol was amended because the 
initial version required a score of at least 2 (RASS score 
2: “Agitated-Frequent non-purposeful movements”) but 
this led to recruitment problems. Therefore, the threshold 
was lowered. If RASS score was at least 1 (used as the 
definition for “epi”), the patients received study medication 
(either lorazepam 3 mg or placebo infused intravenously 
over 1.5 minutes). In addition, patients in both groups 
received 2 mg of haloperidol intravenously. Other drugs 
could be administered and scheduled haloperidol could be 
withheld if this was indicated according to the judgment of 
the attending physician and bedside nurse. As the primary 
outcome, the change in RASS score from baseline to 
8 hours after study drug administration was obtained. 
Results: a total of 90 patients were enrolled [mean age 
62 years; 42 women (47%)]. Of the 90 patients, 58 (64%) 
received the study medication and 52 (90%) completed 
the trial. Patients receiving lorazepam (plus haloperidol) 
for agitation, had significantly lower RASS scores after 
8 hours (−4.1) when compared to the control group 
(placebo plus haloperidol: −2.3; mean difference (MD), 
−1.9; 95% CI, −2.8 to −0.9; P<0.001). In the intervention 
group, significantly less rescue doses of haloperidol were 
needed (median 2.0 mg) compared to the control arm 
(median 4.0 mg; MD −1.0 mg; 95% CI, −2.0 to 0; P=0.009). 
Also, both the blinded informal caregivers and nurses 
perceived significantly more patients in the active arm to be 
comfortable (caregivers: 84% vs. 37%; MD, 47%; 95% CI, 
14% to 73%, P=0 .007; nurses: 77% vs. 30%; MD, 47%; 
95% CI, 17% to 71%, P=0.005). Hypokinesia was the most 
common side effect [intervention group: n=3 patients (19%), 
control group: n=4 patients (27%)]. Results for survival did 
not differ between the two groups.
Authors’  conclusion:  addit ion of  lorazepam to 
haloperidol for the treatment of agitation in delirium was 
more effective than haloperidol alone.
Discussion
Strengths, weaknesses and particularities of the studies
Agar et al. (40)
Strengths: the current paper is one of the first and most 
elaborate interventional studies assessing pharmacotherapy 
delirium of mild to moderate severity in palliative care. 
Therefore, evidence from this trial will be a cornerstone for 
evidence-based guideline development for the treatment 
of delirium in palliative care. Randomization, blinding and 
ITT analysis is impeccable and the choice of the primary 
outcome is meaningful, relevant, chance-sensitive and 
pragmatic, though the timing (72 h after first dose of the 
study regimen) should be noted (see below paragraph 
“particularities”). The presentation of methods and results 
does not leave much room for improvement or open 
question. It should be recognized that in the protocol, 
abstract, introduction and discussion section, the authors 
emphasize that the indication for neuroleptics are certain 
(i.e., behavioral) symptoms in delirious patients, but not 
delirium itself. This is well considered, because it is a known 
and sometimes fatal misunderstanding of many clinicians, 
that neuroleptics were indicated for “disorientation”, as 
“sedatives” (42) or even as prophylaxis for delirium (39). 
Neuroleptics do not only lack approval for these indications, 
their use is known to result in increased morbidity and 
mortality (42,43).
The study was performed as an investigator-initiated-
trial, and the study group did not rely on funding from 
manufacturers. Therefore, the authors` were able to 
conduct the study with an inactive comparator and assess 
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well-known, conventional drugs, which are used in palliative 
care and other fields of medicine for a long time. Because 
the study was performed as a multi-center trial in specialist 
palliative care and hospice institutions, the authors were able 
to include palliative care patients with a variety of advanced 
diseases and different ages, rather than limiting to patients 
with cancer or elderly persons. The latter is often the case 
when trials are performed in cancer centers with palliative 
care departments or nursing homes. From the ethical 
point of view, it is worthwhile mentioning, that rescue 
medication for distressing symptoms was readily available 
for patients in the control- and interventions arms and that 
the administration of study medication could be stopped 
anytime, if this was considered inadequate by the blinded 
bedside nurse and attending physician. Another strength 
of the study is the emphasis the authors have put on non-
pharmacologic and individual measures to treat delirium 
and even more important the precipitating causes of 
delirium. Before pharmacotherapy is initiated for delirium, 
treatment, meticulous assessment and elimination of 
potentially reversible precipitants or aggravators of delirium 
is of utmost importance (i.e., polypharmacy, infections, 
electrolyte abnormalities, absence of hearing and vision aids, 
pain and anxiety, absence of trusted caregivers (“significant 
others”). Agar and colleagues have put significant effort in 
providing such support for all patients in the study (control 
and intervention group) and to describe these measures 
in detail in the publication. Also, it must be noted that 
prevention of delirium is of upmost importance and that 
complex multi-modal non-pharmacological interventions 
are highly effective (44,45). Before pharmacotherapy and 
also non-pharmacologic (“ecobiopsychosocial”) (42,46) 
measures for treating delirium are undertaken, the routine 
screening for and identification of patients at risk for 
delirium and subsequent ecobiopsychosocial measures as 
prophylaxis of delirium are of utmost importance (Table 1). 
Such measures include provision of hearing- and vision 
aids, but also calendars, clocks and instructions for patients 
and informal caregivers (47). For example, in tertiary care 
hospitals, this can be readily implemented by specialist 
nurse-led delirium services (47).
Weaknesses: in the baseline-table of the publication, 
it is evident that most patients that were included did not 
suffer from severe, distressing psychotic symptoms. Yet, it is 
known from various guidelines, that the use of neuroleptics 
should be restricted to those patients who are severely 
affected from these symptoms (47,48). On the one hand, 
this selection bias (wrong indication) (49) might have led 
to the findings that showed superiority of placebo over 
risperidone and haloperidol. On the other hand, it illustrates 
a common, problematic practice in the pharmacologic 
treatment of delirium in palliative care and other field of 
medicine (33). This is, that in contradiction to common 
recommendations (34), neuroleptics are often given for 
“inadequate behavior”, “disorientation” or “psychosocial 
distress”, especially in the elderly and patients with 
dementia (33,34) or even as prophylaxis of delirium (39). As 
it has been mentioned earlier in this article, this is not only 
questionable because of the known negative consequences 
concerning survival of the patients, but also because of 
the impact on quality of life of the patients. Patients are 
prone to experience a relevant increase in distressing 
extrapyramidal effects; moreover, they may seem “calmer” 
if judged by caregiver or health-care-professional, whilst 
experiencing profound distress, as it has been reported by 
patients recovering from hypoactive delirium who recalled 
the experience (42,47). Further research is required in the 
management of palliative care patients with severe delirium 
or with reduced performance status.
Particularities: in the study, the same dose for risperidone 
and haloperidol is used, so doses are not equipotent 
(regarding chlorpromazine equivalents). This resulted in 
very low doses especially for haloperidol and here, especially 
for patients 65 years or older, because an age-adapted 
dosing scheme was used. Specifically, patients 65 years or 
older received a 0.25 mg loading dose along with the first 
dose of 0.25 mg, then 0.5 mg maintenance doses every 
12 hours. Doses could be titrated by 0.25 mg on day 1 and 
by 0.5 mg thereafter to a maximum dose of 2 mg/d. On the 
one hand, it is reasonable to use low doses of neuroleptics, 
because of safety issues (42,48) and other authors have 
reported that on average 2 mg haloperidol per day were an 
effective dose (50). Yet, this dose is surprisingly small and 
little more than the dose often recommended if haloperidol 
is used as an antiemetic in palliative care. Therefore, the 
findings of Agar and colleagues that patients’ survival was 
significantly lower in the haloperidol group are absolutely 
notable. It is an alarming finding and emphasizes that 
safety issues concerning haloperidol in palliative care must 
be assessed vigorously in the future. But it is also possible 
that differences between the three study arms at baseline 
may account for this adverse outcome, because patients in 
the haloperidol group received higher opioid doses than 
patients in the other arms {oral morphine equivalent dose 
[median (interquartile range) (mg/d)]}: haloperidol 33.0 
(0−153.5); risperidone: 6.9 (0−88.2); placebo 15.0 (0−86.4). 
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Table 1 Key recommendations for the therapies of delirium in palliative care
Identify patients at risk for delirium
Routine screening for patients at risk can be performed in any clinical setting with easy means such as the Delirium Observational 
Screening Scale (DOSS)
Provide ecobiopsychosocial interventions as prophylaxis and in case of delirium
For patients at risk and those already experiencing delirium such interventions include the provision of hearing- and vision aids, patient 
and caregiver counselling, stimuli during daytime (activation) and reducing stress at night, validation, provision of clocks and calendars. 
These interventions may be performed by nurse-led counselling services
Prevent, identify and eliminate potential precipitants and aggravators of delirium
This includes for example polypharmacy, pain, unnecessary hospitalisations, infections, withdrawal, electrolyte abnormalities and 
limitations of patient autonomy (i.e., side rails of beds)
Do not initiate pharmacotherapy for disorientation, delirium alone or mild symptoms
In these cases, pharmacotherapy is not helpful, but can even aggravate, precipitate or mask delirium. The latter means that patients 
treated with neuroleptics or benzodiazepines may be “switched” into hypoactive forms of delirium. This has been reported to be as 
distressing as the active form by patients who recover from delirium and recall the experience
Give neuroleptics in case of severe psychotic symptoms
These symptoms include hallucinations, delusions and massive agitation or aggression. Here, neuroleptics can also be given 
subcutaneously. Common substances include haloperidol, risperidone and olanzapine
In case of neuroleptics, be aware of safety issues and distressing side effects
Neuroleptics can lead to profound, potentially painful and distressing or even life-threatening (spasms of the throat) extrapyramidal 
effects. Adverse effects can be minimized by starting with low doses and rather frequent applications (i.e., 2 mg haloperidol given in 
0.5 mg doses 4 times a day is better than 1 mg twice daily). Some neuroleptics (i.e., olanzapine, quetiapine) are associated with less 
extrapyramidal effects. Cardiac arrhythmias are common, especially in patients with pre-existing heart disease. In palliative care, when 
quality of life is the leading therapeutic goal, electrocardiographs before administration of neuroleptics might be negligible in special 
cases, when the effort or burden for the patient is too high
Use benzodiazepines in case of severe agitation
These episodes also include cases of aggression that may be a threat not only for patients themselves, but also caregivers and health-
care-professionals. Substances commonly used include midazolam and lorazepam. Both can be administered intravenously and 
subcutaneously, even though lorazepam is associated with burning and painful sensations on injections
Taper drugs as soon as possible once symptoms are no longer severe
This is important to minimize side effects, ensure maximum patient safety and to prevent masking or aggravation of delirium. Also, 
especially in palliative- and end-of-life care this is necessary to enable patients to communicate with their significant others, express 
wishes and complaints (i.e., pain, breathlessness, nausea) that otherwise remain unidentified
In the future, be aware of new approaches of pharmacotherapy in delirium
These may include the use of melatonin and dexmedetomidine
It cannot be ruled out that for example the potentiation of 
anticholinergic effects of opioids and neuroleptics (drug-
drug interaction) may have led to increased mortality in the 
haloperidol group. It is also remarkable that in this study 
there is a high number of extrapyramidal symptoms were 
reported even in these very small doses. Such symptoms 
are usually not present in doses lower than 3 mg. Dose 
adjustments were rather infrequent and 12-hour intervals 
might be too long to attain an effect. Furthermore, it has 
to be mentioned that the dropout rates for the risperidone 
group (31 of 82 patients) were about twice the rates of 
haloperidol (18 of 81 patients) and placebo (15 of 84 
patients).
The duration of the study was rather short. Already 
72 hours after the administration of the study medication, 
the primary outcome was obtained.  Though it  is 
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recommended, that neuroleptics should be tapered as soon 
as possible in delirium (47,48), 72 hours seems rather short, 
especially because it is known that delirium itself is often 
not reversible (14,16,19,24). Finally, although Agar and 
colleagues mentioned that missing scores were imputed 
using multiple imputations, it is necessary to emphasize 
that missing data can reduce the power and efficiency of a 
study and, unfortunately, can also lead to biased results (51). 
Another particularity of this study was that compared to the 
relatively small doses of neuroleptics, relatively high doses 
of midazolam (2.5 mg intravenous) were allowed as rescue 
medication.
Hui et al. (41)
Strengths: Hui and colleagues managed to conduct one 
of the first interventional studies on the pharmacologic 
treatment of episodes of agitation in delirious palliative care 
patients. Though a standardized RoB analysis, for example 
with the Cochrane Risk of Bias Tool (52) or the Jadad 
score (53) was not undertaken in the focused review 
presented here, the quality of the evidence is most likely 
to exceed that of previous trial. Main reasons for this is 
the randomized, double blind design and the performance 
as an investigator-initiated-trial without funding from 
manufacturers. Hui and coworkers chose to assess an 
absolutely relevant intervention, because benzodiazepines 
are widely used in delirious patient in palliative care and 
other fields of medicine, despite ambiguous or contradictory 
evidence and the known harmful potential of these drugs 
(28,54). The primary outcome (RASS) is well validated, easy 
to comprehend, chance-sensitive and absolutely relevant for 
informal caregivers, health-care-professionals and patient 
safety. Though the authors do not provide information 
about the minimally clinically relevant difference (MCID) 
of this outcome, the power calculation for the trial appears 
reasonable, because a 1.0 difference on a 10-point scale has 
been identified as a sufficient benchmark in other patient-, 
proxy- or professional-rated symptom scales in palliative 
care (55). The authors conclude that lorazepam (in addition 
to haloperidol, when compared to haloperidol alone) was 
superior in treating agitation in delirious patients. They 
did not conclude that that the interventions successfully 
treated delirium itself. This is important, because one 
must distinguish between treating agitation in delirium 
from treating delirium itself, which very often, this source 
of major misunderstanding and malpractice (54). The 
presentation of methods and results is impeccable and does 
not leave many open questions. 
Weaknesses: it should be noted, that the primary 
outcome of this trial might be unfavorable. More precisely, 
a superior effect of the intervention, as measured by the 
primary outcome (RASS), may on the one hand sufficiently 
measure the reduction of agitation (or successful sedation), 
but convey incorrect conclusions. This means that because 
delirious patients who are more sedated or hypoactive may 
as well experience pronounced distress (54,56). The mean 
RASS score among patients treated with lorazepam was −2 
to −3 (minimally responsive to verbal stimulus) compared 
with 0 to −1 (awake and alert, or drowsy) in the control 
arm. This means that less patients in the interventions 
group were able to communicate, what may have been very 
relevant for patients and the significant others, since the 
vast majority of patients died. Furthermore, it might be 
possible, that the combination of haloperidol and lorazepam 
did not treat delirium, but rather masked hyperactive 
delirium symptoms by sedating the patients and, more 
likely, converting those patients to hypoactive delirium, 
which might explain, why patients in the haloperidol and 
lorazepam group had greater severity of delirium than the 
haloperidol and placebo group, despite fewer episodes of 
hyperactivity (57). The impact of lorazepam on delirium 
itself can be found by studying the tables in the manuscript. 
A secondary outcome, the Memorial Delirium Assessment 
Scale (MDAS) (58) was obtained and it is obvious, that 
the intervention did not result in a reduction of delirium 
severity. Taking together ongoing delirium with reduced 
psychomotor activity, it can be argued that lorazepam 
simply shifted patients from hyperactive (or mixed) delirium 
to the hypoactive form, which is just as distressing for 
the patients (54,56). A closer look at the full text of the 
article reveals that 8 hours after administration of the study 
medication, sedation was profound: One of two patients 
scored RASS −3 to −5 [RASS −3: moderate sedation: 
any movement (but no eye contact) to voice; RASS −5: 
unarousable: no response to voice or physical stimulation]. 
Already 30 minutes after being given the study medication, 
1 of 3 patients was RASS −3 to −5. In the control group 
(haloperidol only) this was the case for only 3% (after 
30 minutes) and 8% (after 8 hours) of the patients 
respectively. Interestingly, the mean RASS score at 
baseline was 0 to −1, suggesting that episodes may have 
been moderate hyperactivity or mild restlessness without 
being associated to any danger or distress to self or others 
and thus no indication for a pharmacologic intervention. 
The inclusion of patients with RASS episodes of 1 is 
questionable, because guidelines recommend that the use 
511Annals of Palliative Medicine, Vol 8, No 4 September 2019
© Annals of Palliative Medicine. All rights reserved.   Ann Palliat Med 2019;8(4):504-515 | http://dx.doi.org/10.21037/apm.2019.03.06
of benzodiazepines in delirium should be restricted to 
delirium due to withdrawal and episodes of severe agitation 
or anxiety (47,48). 
Particularities: like in many palliative care trials, the 
patients enrolled in the trial were all suffering from 
advanced cancer, because the palliative care unit was 
associated to a large quartiary US cancer center. This may 
reduce the generalizability of the results, because palliative 
care patients suffer from a variety of diseases from different 
field of medicine (i.e., heart failure, chronic obstructive 
pulmonary disease, frailty, chronic progressive multiple 
sclerosis. Yet, many recommendations in palliative care rely 
on trials with a narrow patient population. Importantly it 
should be noted that no medication is currently licensed 
for use in the management of delirium, so the use of 
medications for the indication of delirium is ‘off-label’. 
In the trial, patients received haloperidol intravenously. 
Many clinicians avoid to give the substance via this route 
of administration, torsade du pointes and other cardiac 
arrhythmias have been reported, especially in the elderly 
and in case of preexisting QT-prolongations or other 
cardiac diseases (50). In palliative care, the subcutaneous 
route would be another well-tolerated option with slower 
onset of action (59). Of importance, Hui and co-workers 
administered daily doses of at least 12 mg haloperidol per 
day as a background medication for delirium. This is far 
more than most other clinicians would consider an average 
effective dose, far more than the neuroleptic dose used 
in the study of Agar and colleagues (40) and far beyond 
the 2 mg that has been reported to be effective in other 
trials (50). Moreover, patients received intravenous 
haloperidol 2 mg along with the study medication (or 
placebo) in case of agitation. This approach warrants 
attention and from the view of the authors of this 
manuscript, this should be viewed critically. First, Hui et al. 
chose relatively high doses of haloperidol. Second, they did 
not apply haloperidol according to its correct indication. 
This means, that haloperidol was given for the treatment 
of delirium (as background medication) and not for the 
treatment of severe psychotic symptoms. The high rate of 
mortality (less than 1 of 3 patients was discharged alive) may 
be explained with the high incidence of delirium in patients 
near the end of life, but an effect of the study medication 
cannot be excluded.
Conclusions
General: in 1996, a landmark randomized controlled 
trial compared haloperidol (N=11), chlorpromazine 
(N=13), and lorazepam (N=6) was conducted for the first-
line management of delirium in HIV patients (60). The 
primary outcome, as assessed by the Delirium Rating Scale, 
improved with haloperidol (P<0.001) and chlorpromazine 
(P<0.001), and no significant differences were detected 
between the two neuroleptic arms (P=0.44). The lorazepam 
arm was terminated prematurely because of excessive 
drowsiness. Understandably, a 2012 Cochrane systematic 
review on drug therapy for delirium in terminally ill adult 
patients concluded that ‘there remains insufficient evidence 
to draw conclusions about the role of drug therapy in the 
treatment of delirium in terminally ill patients’ (61). In 
2017, two landmark RCTs assessing pharmacotherapy of 
delirium in palliative care have become available (40,41). 
Thorough analysis of the evidence provided by these 
trials reveals that recommendations for the pharmacologic 
treatment of delirium can be adopted for palliative care 
(47,48,62). Key recommendations (Table 1) include that 
even though many clinicians still provide antipsychotics in 
mild forms of delirium or even as prophylaxis (50), delirium 
alone or disorientation or so called “biopsychosocial distress 
in dementia” (42) is no indication for the administration of 
drugs. Rather, these drugs are indicated in case of severe 
symptoms (hallucinations, delusions: neuroleptics; agitation 
and anxiety: benzodiazepines). If agitation is triggered by 
hallucinations, delusions or other psychotic symptoms, the 
combination of benzodiazepines and neuroleptics may be 
indicated.
Probably even more important than pharmacotherapy is 
the routine screening of patients at risk for delirium such as 
the Delirium Observational Screening Scale, the confusion 
assessment method for the intensive care unit (CAM-
ICU) or the NuDESC and the provision of individualized 
non-pharmacologic (ecobiopsychosocial) interventions for 
patients and informal caregivers as prophylaxis and therapy 
(63-66). Though delirium is a life-threatening condition 
and especially in palliative care it is very often associated 
with imminent death and often irreversible (22,56), the high 
degree of distress for patients, caregivers and health-care 
professionals demands the meticulous identification and 
treatment of potentially reversible precipitants of delirium. 
Palliative care setting: in patients in a palliative care 
situation, especially in the context of end-of-life- and 
comfort care, quality of life (the reduction and prevention 
of suffering) is the leading and often single therapeutic 
goal. Only a few guidelines focusing on the management 
of delirium at the end of life or in older adults (67). In 
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these cases, issues of patient safety concerning the risk of 
arrhythmias may be less important than in other settings 
and therefore, electro-cardiographs are not mandatory prior 
to the use of haloperidol and other neuroleptics in many 
patients. Still, distressing extrapyramidal effects should 
always be anticipated and biperiden or benztropine should 
be readily available as antidotes. In contrast to patients who 
are treated in curative intent and where the fast tapering 
and stopping of neuroleptics and benzodiazepines is of 
upmost importance once the symptoms are no longer 
severe, it may be appropriate to continue the medication 
specifically in patients in the last days of life and patients 
with structural brain lesions (i.e., metastases) and severe 
symptoms such as agitation. In major trial registries (i.e., 
clinicaltrials.gov), a number of trials assessing melatonin 
(68-73) for the prophylaxis and treatment of delirium 
and have been registered and some are already recruiting 
(e.g., ClinicalTrials.gov Identifier: NCT02615340, 
NCT03013790, NCT02536417). Once data from these 
trials becomes available, these approaches may provide an 
interesting alternative to neuroleptics and benzodiazepines. 
Future studies concerning delirium in palliative care 
must consider the importance of other agents such as 
melatonin or dexmedetomidine (31,33,74) as well as non-
pharmacological interventions to prevent and treat delirium 
(44,45). Regarding delirium in palliative care the following 
questions and issues emerge from a clinical perspective and 
should be considered in further research:
(I) How well has the “palliative care” study population 
been described? Management of delirium in 
“palliative care” patients with expected survival of 
several months differs widely from patients with 
delirium in the dying phase;
(II) What are the underlying causes: management 
of delirium in patients with liver failure and or 
structural brain damage (e.g., metastasis) differ 
widely from treatment in patients with acute fever 
and dehydration;
(III) Which definition is used for diagnosing delirium: 
which clinical signs and symptoms are used 
(following ICD-code), which screening tool should 
be administered (including frequency of repetition) 
and which cut-off-point is regarded as clinically 
relevant;
(IV) What are meaningful outcomes (connected to 
clinical cut-off-point definition) in the management 
of  del i r ium in  pa l l ia t ive  care ,  i .e . ,  which 
perspectives are taken into account: the patient’s, 
the family’s and the professionals’ perspective?
(V) Are new improved statistical methods in delirium 
research necessary given that e.g., delirium status 
changes over time, delirium cannot be assessed 
when patients are comatose, loss to follow-up is 
common to all longitudinal studies of older persons 
(75-78)? 
(VI) What are the most appropriate tools for the 
diagnosis of delirium in the dying phase, especially 
with elderly patients with dementia and comorbid 
delirium-dementia?
The authors argue that any meta-analysis based on 
observational studies or randomized trials will fail to provide 
clear guidance for clinical practice if these definitions have 
not been commonly agreed on, and used as a common 
basis, as long as evidence-based arguments for and against 
prescribing antipsychotics for the treatment of delirium 
exists (79-81).
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